RU2022102328A - Способ лечения фокально-сегментарного гломерулосклероза - Google Patents

Способ лечения фокально-сегментарного гломерулосклероза Download PDF

Info

Publication number
RU2022102328A
RU2022102328A RU2022102328A RU2022102328A RU2022102328A RU 2022102328 A RU2022102328 A RU 2022102328A RU 2022102328 A RU2022102328 A RU 2022102328A RU 2022102328 A RU2022102328 A RU 2022102328A RU 2022102328 A RU2022102328 A RU 2022102328A
Authority
RU
Russia
Prior art keywords
paragraphs
additional therapeutic
therapeutic compounds
patient
disease
Prior art date
Application number
RU2022102328A
Other languages
English (en)
Inventor
Женхуа МИАО
Томaс ЩАЛЛ
Райиндер СИНГХ
Original Assignee
Хемоцентрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хемоцентрикс, Инк. filed Critical Хемоцентрикс, Инк.
Publication of RU2022102328A publication Critical patent/RU2022102328A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (30)

1. Способ лечения заболевания или состояния, выбранного из нефрита, гломерулонефрита, волчаночного нефрита, пиелита, пиелонефрита, пиелоцистита, повреждения клубочков, синдрома Альпорта, IgA-нефропатии, IgG4-нефропатии, мембранно-клеточной интерстициальной нефролитерапии, интерстициальной нефротеинтериальной иммунопротеинотерапии, мембранозной нефропатии, острой долевой нефронии, аденовирусного нефрита, гломерулонефрита, связанного с терапией анти-TNF-α, фибриллярного гломерулонефрита, постинфекционного гломерулонефрита, постстрептококкового гломерулонефрита, болезни Насра или быстро прогрессирующего гломерулонефрита у нуждающегося в этом пациента, включающий назначение пациенту эффективного количества соединения Формулы I:
Figure 00000001
или фармацевтически приемлемой его соли,
где R1 - галоген;
R2 - C1-6 галоалкил;
R3 - галоген или C1-6 алкил;
R4 - водород;
каждый R5 независимо является C1-6 алкилом, -OH или -NH2;
n - это 0; и
каждый из A1 и A2 есть -CH- ;
и A3 является -N- .
2. Способ по п. 1, в котором соединение - это:
Figure 00000002
или его фармацевтически приемлемая соль.
3. Способ по п. 1, в котором соединение - это
Figure 00000003
или его фармацевтически приемлемая соль.
4. Способ по любому из пп. 1-3, где заболевание или состояние представляет собой волчаночный нефрит, IgA-нефропатию или мембранно-клеточную интерстициальную нефролитерапию.
5. Способ по любому из пп. 1-3, где заболевание или состояние представляет собой волчаночный нефрит.
6. Способ по любому из пп. 1-3, где заболевание или состояние представляет собой IgA-нефропатию.
7. Способ по любому из пп. 1-6, в котором соединение или фармацевтически приемлемая его соль водится перорально.
8. Способ по любому из пп. 1-7, в котором соединение или фармацевтически приемлемая его соль назначается дважды в день.
9. Способ по любому из пп. 1-8, в котором соединение или фармацевтически приемлемая его соль назначается один раз в день.
10. Способ по п. 1, дополнительно включающий введение пациенту одного или нескольких дополнительных терапевтических соединений, при этом одно или более дополнительных терапевтических соединений выбирают из группы, состоящей из рамиприла, периндоприла, лизиноприла, аргинина периндоприла, каптоприла, спираприла, хинаприла, эналаприла, имидаприла, фозиноприла, зофеноприла, беназеприла, трандолаприла, верапамила, беназеприла, амлодипина, трандолаприла, P-003, цилазаприла, делаприла, моэксиприла, квинаприла, фозиноприла, темокаприла, лозартана, кандесартана, ирбесартана, телмисартана, олмесартана, валсартана, азилсартана, телмисартана, фимасартана, EMA-401, калия азилсартана медоксомила, спарсентана, кандесартан целиксетила, олмесартана медоксомила, TRV-027, калия лозартана, YH-22189, азилсартана триметилэтаноламина, аллисартана изопропоксила и эпросартана.
11. Способ по п. 1, дополнительно включающий введение пациенту одного или нескольких дополнительных терапевтических соединений, при этом одно или более дополнительных терапевтических соединений выбирают из группы, состоящей из ритуксимаба, дапаглифлозина, спарсентана, абатасепта, DMX-200, пропагерманиума, ирбесартана, лозмапимода, X-M74, Актар Геля, VAR-200, циленгитида, памревлумаба, DEX-M74, фрезолимумаба и SHP-627.
12. Способ по п. 1, дополнительно включающий введение пациенту одного или нескольких дополнительных терапевтических соединений, при этом одно или более дополнительных терапевтических соединений выбирают из группы, состоящей из INT- 767, белимумаба, цинакальцета, ритуксимаба, лозартана, абатасепта, кандесартана, селонсертиба, мио-инозитол гексафосфата, PBI-4050, OMS-721, фостаматиниба, ирбесартана, цанаглифлозина, метоксиполиэтиленгликоль эпоэтина бета, мофетила микофенолата, ALN-CC5, обинутузумаба, ренамезина, палбоциклиба, бозентана, DM-199, будесонида, амифампридина, амифампридина фосфата, дабрафениба, дапаглифлозина, дапаглифлозина пропандиола, кортикотропина, TNT-009, дефибротида, финернона, барицитиниба, тикагрелора, амбризентана, экулизумаба, пегвисоманта, эпалрестата, камостата мезилата, октреотида, октреотида ацетата, GKT-831, уларитида, бардоксолона, бардоксолона метила, толваптана, олмесартана медоксомила, такролимуса, MT-3995, ирбесартана + пропагерманиума, атацисепта, ифетробана, ифетробана натрия, афатиниба, атрасентана, TAK-272, AST-120, фимасартана, GR-MD-02, CS-3150, пирфенидона, омекамтива мекарбила, омекамтива, беклометазон, беклометазон дипропионата, aпaбеталона, спарсентана, ХронСила, азелирагона, памревлумаба, атезидорсена, габапентина энакарбила, габапентина, имидаприла, цендиритида, BMP-7, GLY-230, рекомбинантного эритропоэтин стимулирующего белка, 2MD, терлипрессина, дихлоргидрата пиридоксамина, пиридоксамина, DEX-M74, GSK-2586881, SER-150-DN, клазосентана, блисибимода, AKB-9778, эптотермина альфа, беназеприла, эмрикасана, эпопростенола, DW-1029M, бендазака лизина, селициклиба, BPS-804, авакопана, ALLO-ASC-DFU, SM-101, плозализумаба, берапроста натрия, берапроста, лозмапимода, PEG-bHb-CO, рекомбинантной человеческой щелочной фосфотазы, CXA-10, SAR-407899, BI- 655088, BOT-191, сулодексида, вонапанитаза, соматропина, топироксостата, SB-030, SHP-627, KBP-5074, EA-230, эмаптикап пегола, фенилбутирата натрия, BB-3, Хемалба, тирилазада, ASP-8232, VPI-2690B, октреотида ацетата, EPO-018B, торасемида, рейна, PHN-033, эпросартана, KP-100IT, NCTX, ERC-124, сапроптерина, парнапарина натрия, парнапарина, фенолдопама и витамина D.
13. Способ по любому из пп. 1-12, в котором пациент также подвергается экстракорпоральной очистке крови, аллогенной трансплантации и/или терапии стволовыми клетками.
14. Способ по любому из пп. 10-12, в котором одно или более дополнительных терапевтических соединений назначают одновременно или последовательно.
15. Способ по любому из пп. 10-12, в котором одно или более дополнительных терапевтических соединений назначают как единую фармацевтическую композицию вместе с соединением формулы I или как отдельную фармацевтическую композицию.
16. Способ по п. 1, где заболевание или состояние является мембранно-клеточной интерстициальной нефролитерапией.
RU2022102328A 2016-11-23 2017-11-22 Способ лечения фокально-сегментарного гломерулосклероза RU2022102328A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425832P 2016-11-23 2016-11-23
US62/425,832 2016-11-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2019119129A Division RU2765737C2 (ru) 2016-11-23 2017-11-22 Способ лечения фокально-сегментарного гломерулосклероза

Publications (1)

Publication Number Publication Date
RU2022102328A true RU2022102328A (ru) 2022-04-01

Family

ID=62144131

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019119129A RU2765737C2 (ru) 2016-11-23 2017-11-22 Способ лечения фокально-сегментарного гломерулосклероза
RU2022102328A RU2022102328A (ru) 2016-11-23 2017-11-22 Способ лечения фокально-сегментарного гломерулосклероза

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2019119129A RU2765737C2 (ru) 2016-11-23 2017-11-22 Способ лечения фокально-сегментарного гломерулосклероза

Country Status (13)

Country Link
US (3) US10973809B2 (ru)
EP (2) EP3544602A4 (ru)
JP (3) JP7013464B2 (ru)
KR (1) KR20190088513A (ru)
CN (1) CN110177549A (ru)
AU (1) AU2017363299B2 (ru)
BR (1) BR112019010375A2 (ru)
CA (1) CA3044621A1 (ru)
CL (1) CL2019001381A1 (ru)
IL (2) IL266751B (ru)
MX (2) MX2021014356A (ru)
RU (2) RU2765737C2 (ru)
WO (1) WO2018098353A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017363299B2 (en) * 2016-11-23 2022-12-22 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
JP2020536919A (ja) 2017-10-11 2020-12-17 ケモセントリックス， インコーポレイテッド Ｃｃｒ２アンタゴニストによる巣状分節性糸球体硬化症の治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
JP2023507739A (ja) 2019-12-17 2023-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
CN115768421A (zh) * 2020-04-10 2023-03-07 切诺克治疗公司 治疗糖尿病肾病的方法
CN116761628A (zh) * 2020-12-11 2023-09-15 江苏恒瑞医药股份有限公司 Jak抑制剂在肾脏疾病中的应用
WO2023225163A1 (en) * 2022-05-19 2023-11-23 Chinook Therapeutics, Inc. Methods of treating focal segmental glomerulosclerosis with atrasentan

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3901855A (en) 1974-08-07 1975-08-26 Us Air Force Preparation of polybenzimidazoles
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4227437A (en) 1977-10-11 1980-10-14 Inloes Thomas L Frequency detecting apparatus
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4403607A (en) 1980-05-09 1983-09-13 The Regents Of The University Of California Compatible internal bone fixation plate
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPS6135934A (ja) 1984-07-30 1986-02-20 Tokyo Gas Co Ltd 管路の内張り方法
JPS6145145A (ja) 1984-08-07 1986-03-05 Aisin Warner Ltd 自動変速機
JPS61113060A (ja) 1984-11-08 1986-05-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
DE3825041A1 (de) 1988-07-20 1990-02-15 Schering Ag Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
JPH04364168A (ja) 1990-08-08 1992-12-16 Taisho Pharmaceut Co Ltd スルホンアミドピリジン化合物
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
CA2244785C (en) 1996-02-22 2003-12-02 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
US5780488A (en) 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE360689T1 (de) 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
AR015104A1 (es) 1996-11-13 2001-04-18 Dowelanco Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion.
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6380206B1 (en) 1998-11-23 2002-04-30 Cell Pathways, Inc. Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
JP2000159665A (ja) 1998-11-27 2000-06-13 Nippon Kayaku Co Ltd リウマチの予防または治療剤
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE60013836T2 (de) 1999-06-28 2006-01-19 Janssen Pharmaceutica N.V. Replikationsinhibitoren des respiratorischen synzytialvirus
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001335714A (ja) 2000-03-22 2001-12-04 Fuji Photo Film Co Ltd アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
JP3699910B2 (ja) 2000-10-31 2005-09-28 株式会社東芝 データ伝送装置、データ伝送方法及びプログラム
KR100635703B1 (ko) 2001-06-07 2006-10-17 케모센트릭스, 인크. 세포 이동성 검사
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
JP2003040726A (ja) 2001-07-26 2003-02-13 Daito Kasei Kogyo Kk 化粧料
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003051870A1 (en) 2001-12-18 2003-06-26 Astrazeneca Ab Novel compounds
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
CA2485681C (en) 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20060111351A1 (en) 2002-11-18 2006-05-25 Solomon Ungashe Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
EP2256116A3 (en) 2002-11-18 2011-11-16 ChemoCentryx, Inc. Aryl sulfonamides
AU2003299797A1 (en) 2002-12-19 2004-07-14 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
AU2003290346A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1644008B1 (en) 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
JP5253815B2 (ja) 2005-01-14 2013-07-31 ケモセントリックス， インコーポレイテッド ヘテロアリールスルホンアミドおよびｃｃｒ２
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
WO2007014008A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070219245A1 (en) 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
WO2008008394A1 (en) 2006-07-12 2008-01-17 Transform Pharmaceuticals, Inc. Tizanidine succinate salt forms and methods of making and using the same
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
WO2009009740A1 (en) * 2007-07-12 2009-01-15 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PT3091012T (pt) 2009-12-17 2018-06-27 Centrexion Therapeutics Corp Antagonistas do receptor ccr2 e suas utilizações
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
JP2013538838A (ja) * 2010-09-27 2013-10-17 プロクシマゲン リミテッド ７−ヒドロキシ−ピラゾロ［１，５−ａ］ピリミジン化合物およびｃｃｒ２レセプターアンタゴニストとしてのその使用
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
US20170233737A1 (en) * 2013-11-04 2017-08-17 Noxxon Pharma Ag Means and Methods for the Treatment of Nephropathy
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
AU2017363299B2 (en) * 2016-11-23 2022-12-22 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
JP2020536919A (ja) * 2017-10-11 2020-12-17 ケモセントリックス， インコーポレイテッド Ｃｃｒ２アンタゴニストによる巣状分節性糸球体硬化症の治療

Also Published As

Publication number Publication date
EP3544602A4 (en) 2020-07-08
CN110177549A (zh) 2019-08-27
WO2018098353A1 (en) 2018-05-31
IL294410A (en) 2022-08-01
KR20190088513A (ko) 2019-07-26
JP2024059849A (ja) 2024-05-01
RU2765737C2 (ru) 2022-02-02
EP3544602A1 (en) 2019-10-02
CA3044621A1 (en) 2018-05-31
US20200323832A1 (en) 2020-10-15
IL294410B2 (en) 2024-02-01
IL266751A (en) 2019-07-31
EP4134080A1 (en) 2023-02-15
US20180140587A1 (en) 2018-05-24
JP2019535776A (ja) 2019-12-12
RU2019119129A3 (ru) 2021-03-26
IL294410B1 (en) 2023-10-01
US20220226294A1 (en) 2022-07-21
AU2017363299A1 (en) 2019-06-13
RU2019119129A (ru) 2020-12-24
JP2022058650A (ja) 2022-04-12
IL266751B (en) 2022-07-01
US11324736B2 (en) 2022-05-10
CL2019001381A1 (es) 2019-10-04
JP7013464B2 (ja) 2022-02-15
BR112019010375A2 (pt) 2019-08-27
US10973809B2 (en) 2021-04-13
MX2021014356A (es) 2022-11-24
MX2019005810A (es) 2019-09-11
AU2017363299B2 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
RU2022102328A (ru) Способ лечения фокально-сегментарного гломерулосклероза
KR102573499B1 (ko) 벤조디아제핀 유도체의 제조 방법
RU2018129378A (ru) Способ лечения с3-гломерулопатии
JP2019501935A5 (ru)
TR201901002T4 (tr) Hiperkalemi tedavisine yönelik zirkonyum silikat kullanımı.
CN103209703A (zh) 大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂
CN106304835A (zh) sGC刺激剂
AU2020394421A1 (en) Ion channel modulators
AU2012223232B2 (en) Heterocyclic compounds for the inhibition of PASK
BR112014011981A2 (pt) formulações farmacêuticas
WO2021012014A1 (en) Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
RU2014114499A (ru) Препараты {2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил}амида циклопропанкарбоновой кислоты
WO2018181420A1 (ja) ワクチンアジュバント製剤
CA3193488A1 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
CN103764145A (zh) 作为治疗剂的异噁唑啉类化合物
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
CN1708482A (zh) 作为抗微生物剂的n－磺酰基－4－亚甲基氨基－3－羟基－2－吡啶酮
CN109923101B (zh) 环状化合物
RU2757273C1 (ru) Композиции для предупреждения или лечения увеита
WO2013007792A1 (en) Novel th2 polarizing compounds
AU2016202731B2 (en) Immune-modulating agents and uses therefor
MX2018016250A (es) Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2 ,4-oxadiazol-3-il)benzoico y procesos para su preparacion.
RU2015156417A (ru) Лосмапимод для применения в лечении гломерулярного заболевания
US10570108B2 (en) Substituted benzofuran compounds for the treatment of hepatitis C
US20240101539A1 (en) Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins